Champions Oncology

Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky that was named by TIME as one of the top physicians and scientists in the United States in 2001.
Champions Oncology stock price chart
vol.
change
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Champions Oncology balance sheet

Report period2019 2020 2021 20222023 Q2 24
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Champions Oncology cash flows

Report period2019 2020 2021 20222023 Q2 24 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Champions Oncology multipliers

Report period2019 2020 2021 20222023 Q2 24 TTM
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Champions Oncology profitability

Report period2019 2020 2021 20222023 Q2 24 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Champions Oncology assets
Champions Oncology cash flows

Champions Oncology dividend policy

The company doesn't provide dividend.

Champions Oncology shares

TickerNameTypeNominal valueISINPrice
CSBR:USChampions OncologyCommon share-US15870P3073$4.3
Champions Oncology news
30.03.2022
Champions Oncology's GAAP net income for 9 months of fiscal year 2022 was $0.892 million, down 13.8% from $1.035 million in the prior year. Revenue increased 18.9% to $36.232 million from $30.476 million a year earlier.
14.12.2021
Champions Oncology's GAAP net income for 6M 2022 fiscal year was $105,000, up 38.2% from $76,000 in the previous year. Revenue increased 17.2% to $23.039 million from $19.664 million a year earlier.
Source: {source} pictogram sec.gov
16.03.2021
Champions Oncology's GAAP net income for 9 months of fiscal year 2021 was $816,000, up 11 times from $72,000 in the previous year. Revenue increased 30.4% to $30.476 million from $23.375 million a year earlier.
16.12.2020
Champions Oncology net profit under GAAP for 6 months of fiscal year 2021 was $76 thousand, against a loss of $334 thousand in the previous year. Revenue increased 36.9% to $19.664 million from $14.362 million a year earlier.
General information
Company nameChampions Oncology
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Life Sciences Tools & Services / Life Sciences Tools & Services
Business address855 N. WOLFE STREET SUITE 619 BALTIMORE MD 21205 410-369-0365
Mailing address855 N. WOLFE STREET SUITE 619 BALTIMORE MD 21205
Websitewww.championsoncology.com
Information disclosurewww.sec.gov